Zoetis Inc. $ZTS Position Increased by Cibc World Market Inc.

Cibc World Market Inc. lifted its position in Zoetis Inc. (NYSE:ZTS) by 4.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 150,405 shares of the company’s stock after acquiring an additional 6,249 shares during the period. Cibc World Market Inc.’s holdings in Zoetis were worth $22,007,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ZTS. Halbert Hargrove Global Advisors LLC grew its position in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares in the last quarter. NewSquare Capital LLC boosted its position in shares of Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after buying an additional 85 shares during the period. Financial Consulate Inc. purchased a new position in shares of Zoetis during the third quarter valued at $39,000. SJS Investment Consulting Inc. raised its position in Zoetis by 1,606.3% during the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after buying an additional 257 shares during the period. Finally, TruNorth Capital Management LLC acquired a new position in Zoetis during the third quarter valued at $42,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $128.85 on Thursday. The stock has a market capitalization of $56.79 billion, a P/E ratio of 21.69, a P/E/G ratio of 2.21 and a beta of 0.96. The business has a 50-day moving average of $124.16 and a two-hundred day moving average of $135.79. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.00. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.6%. Zoetis’s dividend payout ratio is presently 35.69%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of research reports. BTIG Research restated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Wednesday, December 3rd. Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, January 28th. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Piper Sandler reiterated a “neutral” rating and issued a $135.00 target price (down previously from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Finally, KeyCorp started coverage on shares of Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $152.45.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.